Trademark: 86663020
Word
ADAPTIVE THERAPEUTICS
Status
Dead
Status Code
602
Status Date
Wednesday, April 27, 2016
Serial Number
86663020
Mark Type
4000
Filing Date
Monday, June 15, 2015
Abandoned Date
Thursday, March 31, 2016

Trademark Owner History

Classifications
42 Scientific and technological services and research and design relating thereto; scientific research, development, engineering, testing, scientific research consultation, and analytical services in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, gene expression, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; development of new technology for others in the fields of medicine, oncology, hematology, auto-immune disorders, infectious diseases, immunology, immunotherapies, immunopharmaceuticals, immune sequencing, immune repertoire quantitation and sequencing, diagnostics, pharmaceuticals, genetics, genetics testing, vaccines and vaccine development, biotechnology, T-cell therapeutics, antibody development and therapeutics, and therapeutic technologies; DNA screening and analysis services; genome amplification; genotyping services for research or analysis purposes; medical and scientific research in the fields of cancer biology and diagnosing and treating cancer; providing medical and scientific research information in the field of clinical trials; scientific research in the field of relative and absolute quantitation of adaptive immune cells in a complex biological sample; scientific research for providing relative and absolute quantitation of adaptive immune cells in a solid tumor sample; scientific research for estimating the relative representation of tumor infiltrating T cells in a solid tumor; scientific research for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; research and development for quantifying the presence and clonality of tumor infiltrating lymphocytes in solid tumors; scientific research, development, engineering, testing, and analytical services for identifying polypeptide pairs of adaptive immune receptor heterodimers of the immune system; scientific research, development, engineering, testing, and analytical services for analyzing and quantifying the diversity of the immune system; scientific research, development, engineering, testing, and analytical services for discovering immune targets; scientific research, engineering, testing, and analytical services for developing monoclonal antibodies and epitope mapping; scientific research for providing sequencing data and analysis of the immune system for vaccine development and vaccine optimization; research and development of vaccines, immunotherapies, and diagnostics; providing technology consultation and research services in the field of immune repertoire analysis, personalized medicine, vaccines, immunotherapies, and diagnostics; scientific research for providing computational analysis of the immune repertoire; providing clinical diagnostic assays and diagnostic or prognostic testing for detection of minimal residual disease in lymphoid malignancies; providing analysis, evaluation, and clinical reports of a patient's immune repertoire, including T cell or B cell clonal diversity and clone frequency; providing assays for tracking clones in an immune repertoire over time; providing diagnostic assays and diagnostic or prognostic testing for residual disease, and the analysis, evaluation, and reports of those test results to help healthcare professionals determine a patient's clinical diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly; research, development, engineering, testing, and analytical services in the fields of vaccines, screening and detecting diseases, medicine, and therapeutics; research and development of vaccines, immunotherapies, medical diagnostics kits, and therapeutics; research and development of diagnostic test kits for screening and detecting diseases; laboratory research and testing services relating to vaccines, screening and detecting diseases, medicine, and therapeutics; computer services; design and development of computer hardware and software; computer services, namely, software as a service (SAAS) services featuring software that provides information, test results for screening and detecting diseases, and the analysis, evaluation, and reporting of those test results to healthcare professionals and patients; research and diagnostic services for identifying antigen-specific T cells for therapeutic use
44 Medical services; medical analysis and diagnostic services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; providing medical diagnostic testing for the treatment of cancer; providing medical testing for immune responses to immunotherapy or cancer treatment; providing medical quantitative analysis and testing services in the fields of cancer biology, immunology, pharmaceuticals and vaccines for diagnostic or treatment purposes; medical testing for the prognosis and staging of patients with solid tumors for treatment purposes; therapeutic services; therapeutic services for the treatment of diseases; therapeutic services for the treatment of cancer

Trademark Events
Feb 13, 2018
Teas Change Of Correspondence Received
Apr 27, 2016
Abandonment Notice Mailed - Failure To Respond
Apr 27, 2016
Abandonment - Failure To Respond Or Late Response
Sep 30, 2015
Notification Of Non-Final Action E-Mailed
Sep 30, 2015
Non-Final Action E-Mailed
Sep 30, 2015
Non-Final Action Written
Sep 23, 2015
Assigned To Examiner
Jun 18, 2015
New Application Office Supplied Data Entered In Tram
Jun 18, 2015
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24